# Clinical Trial: OPTIMIZE-HF

**Trial ID**: NCT2024001
**Title**: Optimizing Heart Failure Management: A Randomized Controlled Trial
**Phase**: Phase III
**Status**: Active, Recruiting
**Start Date**: January 15, 2024
**Estimated Completion**: December 31, 2026

## Study Overview
A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of a novel beta-blocker combination therapy in patients with chronic heart failure with reduced ejection fraction (HFrEF).

## Principal Investigator
- **Name**: Dr. Sarah Johnson, MD
- **Institution**: XYZ Hospital, Division of Cardiology
- **Contact**: sarah.johnson@xyzhospital.org

## Co-Investigators
- Dr. Michael Chen, MD (Cardiology)
- Dr. Lisa Wong, MD (Cardiology)
- Dr. Amanda Torres, MD (Emergency Medicine)

## Funding
- **Primary Sponsor**: National Heart, Lung, and Blood Institute (NHLBI)
- **Grant Number**: R01-HL-2024001
- **Total Funding**: $4,250,000
- **Duration**: 3 years

## Study Design
- **Design**: Randomized, double-blind, placebo-controlled
- **Allocation**: 1:1 randomization
- **Intervention Model**: Parallel assignment
- **Masking**: Quadruple (participant, care provider, investigator, outcomes assessor)
- **Primary Purpose**: Treatment

## Eligibility Criteria

### Inclusion Criteria
- Age ≥ 18 years
- Diagnosis of HFrEF (LVEF ≤ 40%) within past 12 months
- NYHA Class II-III symptoms
- Stable on standard HF therapy for ≥ 4 weeks
- Able to provide informed consent

### Exclusion Criteria
- Recent acute coronary syndrome (< 3 months)
- Severe renal impairment (eGFR < 30 mL/min/1.73m²)
- Liver cirrhosis or active hepatitis
- Pregnancy or lactation
- Known hypersensitivity to study medication
- Participation in another interventional trial

## Study Interventions
- **Experimental Group**: Novel beta-blocker combination (carvedilol + nebivolol) titrated to target dose
- **Control Group**: Standard beta-blocker therapy (carvedilol or metoprolol) per guidelines
- **Duration**: 12 months of treatment
- **Follow-up**: 24 months total

## Primary Outcome Measures
- **Time Frame**: 12 months
- **Primary Endpoint**: Composite of cardiovascular death or heart failure hospitalization
- **Secondary Endpoints**:
  - Change in LVEF from baseline
  - Quality of life (MLHFQ score)
  - Exercise capacity (6-minute walk test)
  - NT-proBNP levels

## Sample Size
- **Target Enrollment**: 1,200 patients
- **Current Enrollment**: 847 patients (70.6% complete)
- **Study Centers**: 15 academic medical centers
- **XYZ Hospital Enrollment**: 120 patients (target: 150)

## Recruitment Status
- **Overall**: Actively recruiting
- **XYZ Hospital**: Actively recruiting (enrolling 2-3 patients/week)
- **Diversity**: 35% female, 28% minority representation
- **Geographic**: Midwest and Southern US states

## Data Collection
- **CRF Completion**: Electronic data capture system
- **Monitoring**: On-site monitoring visits quarterly
- **DSMB Review**: Safety data reviewed every 6 months
- **Database Lock**: Expected June 2026

## Regulatory Information
- **IRB Approval**: XYZ Hospital IRB #2023-045 (approved December 2023)
- **FDA IND**: IND #145678 (Phase III exemption)
- **ClinicalTrials.gov**: Registered December 2023
- **Insurance**: Comprehensive liability coverage in place

## Study Timeline
- **Q1 2024**: Enrollment ramp-up and training
- **Q2-Q3 2024**: Peak enrollment period
- **Q4 2024**: Enrollment completion target
- **2025**: Treatment and follow-up phase
- **2026**: Data analysis and manuscript preparation

## Budget Breakdown
- **Personnel**: $1,800,000 (research coordinators, data managers)
- **Study Drug**: $950,000 (investigational medication)
- **Laboratory**: $600,000 (biomarker testing)
- **Imaging**: $400,000 (echocardiograms)
- **Monitoring**: $300,000 (CRO and DSMB)
- **Administrative**: $200,000 (IRB, regulatory)

## Publications and Presentations
- **Planned Publications**: 3-4 manuscripts
- **Conference Presentations**: ACC 2025, AHA 2025, HFSA 2026
- **Data Sharing**: De-identified data available after primary publication

## Challenges and Solutions
- **Slow Enrollment**: Implemented community outreach program
- **Protocol Deviations**: Enhanced training and monitoring
- **Retention Issues**: Patient navigation and reminder systems

## Contact Information
- **Study Coordinator**: Jennifer Walsh, RN, MSN
- **Phone**: (555) 123-4567 ext. 7890
- **Email**: optimize-hf@xyzhospital.org
- **Website**: www.xyzhospital.org/research/optimize-hf